U.S. patent application number 10/788954 was filed with the patent office on 2004-09-02 for polyisoprene articles and process for making the same.
Invention is credited to Wang, Shiping, Wenig, Randell, Wong, Weicheong, Yeh, Yun-Siung Tony.
Application Number | 20040169317 10/788954 |
Document ID | / |
Family ID | 23050823 |
Filed Date | 2004-09-02 |
United States Patent
Application |
20040169317 |
Kind Code |
A1 |
Wang, Shiping ; et
al. |
September 2, 2004 |
Polyisoprene articles and process for making the same
Abstract
The invention disclosed herein relates to an improved process
for making elastomeric polyisoprene articles. In particular, the
process of the invention is a system which produces synthetic
polyisoprene articles exhibiting tensile strength properties
similar to that of solvent-based processes using natural rubber
latex. The process comprises an accelerator composition at the
pre-cure stage comprising a dithiocarbamate, a thiazole and a
guanidine compound. In a preferred embodiment, the accelerator
composition comprises zinc diethyldithiocarbamate (ZDEC), zinc
2-mercaptobenzothiazole (ZMBT) and diphenyl guanidine (DPG), in
conjunction with a stabilizer, such as sodium caseinate. The
invention also includes an elastomeric polyisoprene product made by
the process, such as a surgeon's glove.
Inventors: |
Wang, Shiping;
(Libertyville, IL) ; Yeh, Yun-Siung Tony;
(Libertyville, IL) ; Wenig, Randell; (Batavia,
IL) ; Wong, Weicheong; (Kedah, MY) |
Correspondence
Address: |
Allegiance Corporation
Attn: Kim Luna
KB-1A
1430 Waukegan Road
McGaw
IL
60083
US
|
Family ID: |
23050823 |
Appl. No.: |
10/788954 |
Filed: |
March 1, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10788954 |
Mar 1, 2004 |
|
|
|
10096226 |
Mar 12, 2002 |
|
|
|
60275087 |
Mar 12, 2001 |
|
|
|
Current U.S.
Class: |
264/301 ;
524/104 |
Current CPC
Class: |
C08J 5/02 20130101; C08L
9/10 20130101; C08J 2309/00 20130101; C08K 5/0025 20130101; C08K
5/39 20130101; C08L 89/005 20130101; Y10T 428/1386 20150115; C08K
5/0025 20130101; C08L 21/00 20130101; C08K 5/0025 20130101; C08L
9/10 20130101; C08K 5/39 20130101; C08L 21/00 20130101; C08L 9/10
20130101; C08L 2666/26 20130101 |
Class at
Publication: |
264/301 ;
524/104 |
International
Class: |
B29C 041/14; C08K
005/34 |
Claims
What is claimed is:
1. A process of making an elastomeric polyisoprene article
comprising the steps of: a) preparing a compounded latex
composition containing an accelerator composition and a stabilizer,
said accelerator composition comprising a dithiocarbamate, a
thiazole and a guanidine compound; b) dipping a former into said
compounded latex composition; and c) curing said compounded latex
composition on said former to form said elastomeric polyisoprene
article.
2. The process of claim 1, wherein said elastomeric polyisoprene
article is a glove.
3. The process of claim 1, wherein said elastomeric polyisoprene
article is a condom.
4. The process of claim 1, wherein said elastomeric polyisoprene
article is a probe cover.
5. The process of claim 1, wherein said elastomeric polyisoprene
article is a catheter.
6. The process of claim 1, wherein said accelerator composition
comprises: zinc diethyldithiocarbamate; zinc
2-mercaptobenzothiazole; and diphenyl guanidine.
7. The process of claim 1, wherein said stabilizer comprises a milk
protein salt.
8. The process of claim 7, wherein said stabilizer comprises sodium
caseinate.
9. The process of claim 1, wherein said accelerator composition
comprises: a dithiocarbamate to thiazole to guanidine phr ratio of
from about 0.50 phr to about 1.00 phr dithiocarbamate, from about
0.50 phr to about 1.00 phr thiazole, from about 0.50 phr to about
1.00 phr guanidine, per 100.0 phr polyisoprene of the compounded
latex composition.
10. A synthetic elastomeric polyisoprene article having a tensile
of greater than about 3000 psi as measured in accordance with ASTM
D412, said article being prepared by a process comprising the steps
of: a) preparing a compounded latex composition containing an
accelerator composition and a stabilizer, said
accelerator-composition comprising a dithiocarbamate, a thiazole
and a guanidine compound, and a stabilizer; b) dipping a former
into said compounded latex composition; and c) curing said
compounded latex composition on said former.
11. The article of claim 10, wherein the article is a glove.
12. The article of claim 10, wherein the article is a condom.
13. The article of claim 10, wherein the article is a probe
cover.
14. The article of claim 10 wherein the article is a catheter.
15. The article of claim 10, wherein said accelerator composition
comprises: zinc diethyldithiocarbamate; zinc
2-mercaptobenzothiazole; and diphenyl guanidine.
16. The article of claim 10, wherein said stabilizer comprises a
milk protein salt.
17. The article of claim 16, wherein said stabilizer comprises
sodium caseinate.
18. The article of claim 10, wherein said accelerator composition
comprises: a dithiocarbamate to thiazole to guanidine phr ratio of
from about 0.50 phr to about 1.00 phr dithiocarbamate, from about
0.50 phr to about 1.00 phr thiazole, and from about 0.50 phr to
about 1.00 phr guanidine, per 100.0 phr polyisoprene of the
compounded latex composition.
19. A polyisoprene latex composition comprising: a dithiocarbamate
compound; a thiazole compound; a guanidine compound; and a
stabilizer.
20. The latex composition of claim 19 wherein the latex composition
comprises: zinc diethyldithiocarbamate; zinc
2-mercaptobenzothiazole; diphenyl guanidine; and sodium
caseinate.
21. An accelerator composition for use in a process for making
elastomeric polyisoprene articles, said accelerator composition
consisting essentially of: a dithiocarbamate compound; a thiazole
compound; and a guanidine compound; wherein the phr dry weight
ratio of each of the dithiocarbamate, thiazole and guanidine ranges
from about 0.50 to about 1.00 per 100.0 parts polyisoprene.
22. A glove composed of polyisoprene and having a tensile strength
of greater than 3000 psi as measured in accordance with ASTM D412,
said glove being prepared from a polyisoprene latex composition
comprising a dithiocarbamate compound, a thiazole compound, and a
guanidine compound.
23. The glove of claim 18, wherein said polyisoprene latex
composition further comprises sodium caseinate.
24. The glove of claim 19, wherein said latex composition is stored
for up to about 7 days.
Description
RELATED APPLICATION DATA
[0001] This application is based on U.S. provisional patent
application Serial No. 60/275,087 filed on March 12, 2001.
FIELD OF THE INVENTION
[0002] The invention relates to the field of elastomeric articles
used in the medical field. In particular, the invention relates to
improvements to the process of making elastomeric polyisoprene
articles for medical applications.
BACKGROUND OF THE INVENTION
[0003] The manufacturing process for producing elastomeric articles
from natural or synthetic rubber latex involves a curing step
during which crosslinking or vulcanization through sulfur groups
occurs between the polymer units. Conventional processes for making
elastomeric articles from natural or synthetic latex typically
involve preparing a latex dispersion or emulsion, dipping a former
in the shape of the article to be manufactured into the latex and
curing the latex while on the former. Desirable properties of
certain elastomeric articles such as tensile strength are
substantially affected by the cross-linking and curing stages of
the manufacturing process.
[0004] The use of vulcanizing or sulfur cross-linking accelerator
compounds in the manufacture of rubber articles is well-known.
Conventional vulcanization accelerators include dithiocarbamates,
thiazoles, guanidines, thioureas, amines, disulfides, thiurams,
xanthates and sulfenamides. The use of vulcanization accelerators
in the manufacture of polyisoprene rubber is disclosed in D'Sidocky
et al., U.S. Pat. No. 5,744,552 and Rauchfuss et al., U.S. Pat. No.
6,114,469. Certain fields in which elastomeric articles are needed,
such as the medical field, utilize specific types of equipment and
processing techniques which accommodate the specific performance
and regulatory requirements of the particular article produced.
[0005] The use of natural rubber latex in the manufacture of
certain articles such as medical gloves has been associated with
disadvantageous properties, such as allergic reactions believed by
some to be caused by natural proteins or allergens present within
the natural rubber latex and the final product. Of increasing
interest in the medical field, particularly in the field of gloves,
are synthetic elastomeric products and manufacturing processes
which altogether reduce, or altogether avoid, the likelihood of
potential adverse reactions of the user or wearer.
[0006] Synthetic elastomeric polyisoprene articles such as gloves
are known and are of interest in the art as an alternative to the
use of natural latex. Commercially available synthetic gloves
include those elastomers composed of polychloroprene (neoprene),
carboxylated acrylonitrile butadiene (nitrile),
styrene-isoprene-styrene/styrene-ethyl- ene-butylene-styrene block
co-polymers, polyurethane, and polyisoprene. Polyisoprene is one of
the most preferred polymers due to its chemical similarity to
natural rubber as well as its physical properties such as feel,
softness, modulus, elongation and tensile strength. One such
polyisoprene glove is commercially available from Maxxim Medical
(Clearwater, Fla.).
[0007] A majority of glove manufacturing processes are water-based
dipping systems. It is known that solvent-based systems are
possible for polyisoprene, although such systems are poorly suited
for the manufacture and molding of elastomeric articles for medical
applications. One difficulty in the field of gloves, for example,
is the design of processes and materials which will produce a thin
elastomeric article having desirable properties such as high
tensile strength. Another disadvantage of solvent-based systems is
solvent toxicity. Process and materials which would obviate or
reduce the need for the use of toxic solvents while at the same
time yielding a product having desirable properties for medical
applications are thus still being explored.
[0008] Accordingly, there exists a need in the medical device field
for improved manufacturing processes for making synthetic
elastomeric articles. Especially desirable would be processes which
can produce polyisoprene articles, such as surgical gloves, which
possess the desirable properties found in the natural rubber
counterpart, while at the same time permitting economical and
cost-effective manufacturing.
SUMMARY OF THE INVENTION
[0009] Applicants have discovered a three-part accelerator
composition for sulfur cross-linkable polyisoprene latex which can
be used with latex in a process for making elastomeric articles
having the desirable properties (e.g., tensile strength) similar to
that of natural rubber but without the presence of natural rubber
latex proteins and allergens. Another advantage is that the
accelerator system is suitable for medical applications where thin
molded elastomeric articles are required, such as gloves.
Furthermore, the accelerator composition and process of the
invention permits the use of a solvent-free, water-based process
system, as opposed to a solvent based process system. The resultant
article has properties similar to those produced using the
solvent-based system. Accordingly, the use of solvents can be
reduced or avoided and solvent toxicity can likewise be avoided
using the invention.
[0010] Another advantage of the invention is that conventional
manufacturing equipment and most readily-available materials can be
used in accordance with the invention to make the synthetic
polyisoprene glove without the need for new or costly additional
materials or equipment. Further, no complicated new process steps
are required by the invention and the invention can be readily
incorporated into existing glove making processes and systems.
[0011] Another aspect of the invention is that the compounded (or
ready to use) polyisoprene latex composition formulated in
accordance with the invention exhibits prolonged storage stability.
For example, the pre-cure storage stability of the compounded
polyisoprene latex composition (i.e., the time period prior to the
use of the compounded polyisoprene latex composition in the dipping
and curing stages) can extend up to about 8 days, in contrast to
the typical current 3 to 5 day time period. By extending storage
life of the latex, the amount of wasted latex can be significantly
reduced and greater flexibility in scheduling manufacturing
processes is permitted.
[0012] Yet another advantage is that the process of the invention
allows for significantly reduced pre-cure process parameters (lower
temperature and shorter time periods than conventionally used) and
lower dipping temperatures in the manufacturing process.
Accordingly, significant cost and resource advantages are provided
over conventional manufacturing practices.
[0013] The invention provides for a process of making a synthetic
elastomeric polyisoprene article comprising the steps of: a)
preparing a compounded polyisoprene latex composition containing an
accelerator composition containing a dithiocarbamate, a thiazole
and a guanidine compound; b) dipping a former into said compounded
polyisoprene latex composition; and c) curing said compounded
polyisoprene composition on said former. Additionally, the initial
pre-cure processing (i.e., prior to storage and article
manufacture) can be performed at temperatures of less than
35.degree. C. and in time periods as short as ranging from about 90
minutes (1.5 hours) to about 150 minutes (2.5 hours), preferably
about 120 minutes (2.0 hours). The compounded polyisoprene latex
composition can be stored for periods up to about 8 days at ambient
temperatures (ranging from about 15.degree. C. to about 20.degree.
C.). Lower temperatures can be used for the latex dipping step as
well
[0014] The invention also provides for a synthetic elastomeric
polyisoprene article made by a process comprising the steps of: a)
preparing a compounded polyisoprene latex composition comprising an
accelerator composition comprising a dithiocarbamate, a thiazole
and a guanidine compound; b) pre-curing said compounded
polyisoprene latex composition c) dipping a former into said
compounded polyisoprene latex composition; and d) curing said
compounded polyisoprene composition on said former. Elastomeric
articles made by the process of the invention can exhibit tensile
strengths of over 3000 psi (as measured in accordance with ASTM
D412) even after as much as 7 days of latex storage prior to use in
the article manufacturing process.
[0015] The invention further provides for a synthetic polyisoprene
latex composition comprising:
[0016] polyisoprene latex;
[0017] a dithiocarbamate compound;
[0018] a thiazole compound; and
[0019] a guanidine compound.
[0020] The invention also provides for an accelerator composition
for use in making elastomeric polyisoprene articles consisting
essentially of:
[0021] a dithiocarbamate compound;
[0022] a thiazole compound;
[0023] a guanidine compound;
[0024] wherein the phr (parts per hundred) dry weight ratio of each
of the dithiocarbamate; thiazole; and guanidine ranges from about
0.50 to about 1.00 per 100.0 parts polyisoprene.
[0025] In a preferred embodiment, the accelerator composition
comprises zinc diethylthiocarbamate (ZDEC), zinc
2-mercaptobenzothiazole (ZMBT) and diphenyl guanidine (DPG) and
used in conjunction with a stabilizer. Preferably, the stabilizer
is an alkali earth metal caseinate salt, such as sodium
caseinate.
DETAILED DESCRIPTION OF THE INVENTION
[0026] The accelerator composition of the invention can be used in
conjunction with conventional equipment and materials otherwise
known to be used in the manufacture of elastomeric articles
composed of polyisoprene. In general, the process begins with the
preparation of the compounded polyisoprene latex composition. The
synthetic polyisoprene latex is combined with the accelerator
composition, a stabilizer, and additional ingredients to prepare
the polyisoprene latex composition in accordance with the
invention. The function of the accelerator is to increase the rate
of vulcanization, or the cross-linking of polyisoprene to enhance
the curing properties of the latex during the curing stages of the
process. Prior to the dipping and curing steps, the compounded
latex including the accelerator composition can be used immediately
or stored for a period of time prior to its employment in the
dipping process.
[0027] When the compounded polyisoprene latex composition is ready
for use or following storage, a former in the overall shape of the
article to be manufactured is first dipped into a coagulant
composition to form a coagulant layer directly on the former. Next,
the coagulant-coated former is dried and then dipped into the
compounded polyisoprene latex composition.
[0028] The latex-covered former is then subjected to the curing
step. The latex is cured directly onto the former at elevated
temperatures thereby producing an article in the shape of the
former. Further steps are typically performed as well, such as
leaching with water, beading the cuff, and the like. These
techniques are well-known in the art. Additional post-treatment
processes and techniques steps are often performed as well, such as
lubrication and coating, halogenation (e.g., chlorination), and
sterilization.
[0029] A variety of elastomeric articles can be made in accordance
with the invention. Such elastomeric articles include, but are not
limited to, medical gloves, condoms, probe covers (e.g., for
ultrasonic or transducer probes), dental dams, finger cots,
catheters, and the like. As the invention provides numerous
advantages and benefits in a number of ways, any form of
elastomeric article which can be composed of polyisoprene can
benefit from the use of the invention.
[0030] Polyisoprene latex is the major component of the pre-cure
latex composition. Suitable polyisoprene latex which can be used is
readily available and can be obtained from a number of commercial
sources, including but not limited to, Kraton.TM. Corporation,
Houston, Tex.; Shell International Corporation, Houston, Tex.; Apex
Medical Technologies, Inc. San Diego, Calif.; and Aqualast.TM.
E0501 available from Lord Corporation, Erie, Pa. In addition to
polyisoprene, polyisoprene co-polymers and polyisoprene blends can
be used as well. Polyisoprene co-polymers which can be used include
any co-polymer having an isoprene monomer unit and having
sufficiently similar chemical structural and properties of
polyisoprene to exhibit the desirable properties of the
polyisoprene product when combined with the accelerator composition
and made according to the process of the invention. Suitable
polyisoprene blends can include, but are not limited to: natural
rubber latex; polydiene and its co-polymers, such as polybutadiene;
substituted polydiene, such as polychloroprene; thermoplastic
materials, such as polyurethane; and the like.
[0031] The accelerator composition of the invention comprises at
least one dithiocarbamate, at least one thiazole, and at least one
guanidine compound. Preferably, the dithiocarbamate compound for
use with the invention is zinc diethyldithiocarbamate, also known
as ZDEC or ZDC. Suitable ZDEC which can be used includes Bostex.TM.
561 (commercially available from Akron Dispersions, Akron, Ohio).
The preferred thiazole compound for use in the invention is zinc
2-mercaptobenzothiazole, also known as zinc dimercaptobenzothiazole
or ZMBT. Suitable ZMBT which can be used includes Bostex.TM. 482A
(commercially available from Akron Dispersions, Akron, Ohio). In a
preferred embodiment, the guanidine compound used in the
accelerator composition is diphenyl guanidine, also known as DPG.
Suitable DPG which can be used includes Bostex.TM. 417
(commercially available from Akron Dispersions, Akron, Ohio).
[0032] Other dithiocarbamate, thiazole and guanidine derivatives
can also be use in accordance with the invention, provided each is
chemically compatible with, i.e., does not substantially interfere
with the functionality of, the remaining two accelerator compounds
used. Dithiocarbamate derivatives which can also be used include
zinc dimethyldithiocarbamate (ZMD), sodium dimethyldithiocarbamate
(SMD), bismuth dimethyldithiocarbamate (BMD), calcium
dimethyldithiocarbamate (CAMD), copper dimethyldithiocarbamate
(CMD), lead dimethyldithiocarbamate (LMD), selenium
dimethyldithiocarbamate (SEMD), sodium diethyldithiocarbamate
(SDC), ammonium diethyldithiocarbamate (ADC), copper
diethyldithiocarbamate (CDC), lead diethyldithiocarbamate (LDC),
selenium diethyldithiocarbamate (SEDC), tellurium
diethyldithiocarbamate (TEDC), zinc dibutyldithiocarbamate (ZBUD),
sodium dibutyldithiocarbamate (SBUD), dibutyl ammonium
dibutyldithiocarbamate (DBUD), zinc dibenzyldithiocarbamate (ZBD),
zinc methylphenyl dithiocarbamate (ZMPD), zinc ethylphenyl
dithiocarbamate (ZEPD), zinc pentamethylene dithiocarbamate (ZPD),
calcium pentamethylene dithiocarbamate (CDPD), lead pentamethylene
dithiocarbamate (LPD), sodium pentamethylene dithiocarbamate (SPD),
piperidine pentamethylene dithiocarbamate (PPD), and zinc
lopetidene dithiocarbamate (ZLD).
[0033] Other thiazole derivatives which can be used include
2-mercaptobenzothiazole (MBT), copper dimercaptobenzothiazole
(CMBT), benzthiazyl disulphide (MBTS), and
2-(2',4'-dinitrophenylthio) benzthiazole (DMBT).
[0034] Other guanidine derivatives which can be used include
diphenyl guanidine acetate (DPGA), diphenyl guanidine oxalate
(DPGO), diphenyl guanidine phthalate (DPGP), di-o-tolyl guanidine
(DOTG), phenyl-o-tolyl guanidine (POTG), and triphenyl guanidine
(TPG).
[0035] The proportions and ratios of the ingredients of the
accelerator composition can vary somewhat provided all three of the
ingredients, i.e., dithiocarbamate, thiazole and guanidine
compounds, are present. With respect to the preferred accelerator
ingredients, each of the accelerator compounds zinc
diethyldithiocarbamate (ZDEC), zinc 2-mercaptobenzothiazole (ZMBT)
and diphenyl guanidine (DPG) can be present in an individual amount
ranging from about 0.50 phr (parts by weight per 100 parts by
weight of rubber) to about 1.00 phr dry weight per 100 parts
polyisoprene. In other words, the accelerator compositions of the
invention comprise ZDEC:ZMBT:DPG phr dry weight ratios ranging
respectively from about 0.50:0.50:0.50 phr to about 1.00:1.00:1.00
phr.
[0036] In a preferred embodiment, a stabilizer is used in
conjunction with the accelerator composition. Any stabilizer known
in the art useful in curable latex systems can be used provided it
is chemically compatible with the other ingredients and provides
the desired function, i.e., prolongs stabilization of the pre-cure
compounded polyisoprene latex. A variety of stabilizers can be
used, including but not limited to, milk protein salts, anionic
surfactants such as sodium lauryl sulfates, and sorbitan fatty acid
esters.
[0037] Milk protein salts are preferred for use as the stabilizer.
In particular, alkali earth metal caseinate salts are preferred.
Alkali earth metal caseinate salts which can be used in accordance
with the invention include, but are not limited to, sodium
caseinate, potassium caseinate, manganese caseinate and zinc
caseinate, and combinations thereof. Most preferred for use as the
stabilizer is sodium caseinate (commercially available from
Technical Industries, Inc., Peacedale, R.I.).
[0038] Anionic surfactants which can be used as stabilizers for the
invention include Rhodopex.RTM. ES (a composition having a sodium
lauryl (3) sulfate active available from Rhodia, Cranbury, N.J.)
and Rhodacal.RTM. DS-10 (a composition having a branched sodium
dodecylbenzene active available from Rhodia, Cranbury, N.J.).
Sorbitan fatty acid ester surfactants which can be used as
stabilizers in the invention include polyoxyethylene sorbitan fatty
acid esters such as Tween.RTM. 80 (a polysorbate available from ICI
Americas, Inc., Wilmington, Del.).
[0039] The amount of stabilizer present in the procure polyisoprene
latex composition is preferably ranges from about 0.50 phr dry
weight to about 1.00 phr dry weight (per 100.00 parts dry weight
polyisoprene). Preferably, the amount of stabilizer is present in
an amount of about 0.75 phr dry weight.
[0040] In addition to the polyisoprene, accelerator composition and
stabilizer, additional ingredients which enhance or facilitate the
manufacturing process can be included in the compounded
polyisoprene latex composition as well. The compounded polyisoprene
latex composition can also include catalysts (or accelerator
initiators) such as alkali earth metal oxides and methyl oxides,
preferably zinc oxide (ZnO) (commercially available from Maxxim
Medical, Eaton, Ohio); curing (or cross-linking) agents such as
elemental Sulfur (e.g., Bostex.TM. 378 commercially available from
Akron Dispersion, Akron, Ohio), organic sulfides or other sulfur
donor compounds; and anti-oxidants, such as Wingstay.TM. L (e.g.,
butylated reaction product of p-cresol and dicyclopentadiene (DCPD)
such as Bostex.TM. 24 available from Akron Dispersion, Akron,
Ohio).
[0041] Preparation of Polyisoprene Latex Composition
[0042] The compounded polyisoprene latex composition in accordance
with the invention can be prepared using the following general
procedure:
[0043] Polyisoprene latex (typically 60% solids) and the stabilizer
(e.g., sodium caseinate) are combined at ambient temperature (about
20.degree. to about 25.degree. C.). After mixing for a period of
time, the mixture is then diluted to 40% solids in water. Wingstay
L is then added and the mixture is stirred for approximately 15
minutes. At this point, the pH can be adjusted to a range of about
8.5 to 9.0. Zinc oxide is added, followed by the sulfur and
accelerator compounds. Preferred accelerator compounds are ZDEC,
ZMBT and DPG and are added in ratios ranging from 0.50:0.50:0.50
phr to 1.00:1.00:1.00 phr dry weight per 100.0 parts polyisoprene.
The mixture is then heated to a temperature within a range of about
20.degree. C. to about 40.degree. C., preferably from about
25.degree. C. to about 30.degree. C., while continuously stirring
for a time period ranging from about 1.5 hours to about 2.5 hours,
preferably about 2 hours, using a magnetic stirrer and heating
plate.
[0044] The mixture is then cooled to a temperature ranging of less
than about 25.degree. C., typically ranging from about 15.degree.
C. to about 20.degree. C. The compounded latex is preferably stored
at ambient temperatures ranging from about 15.degree. to about
20.degree. C. At these temperatures, the compounded polyisoprene
latex composition can be stored for periods lasting up to about 8
days prior to its use in the dipping and curing process.
[0045] Preparation of a Polyisoprene Glove
[0046] Initially, the pH of the compounded polyisoprene latex can
be adjusted to a pH of approximately 10. A glove former is
pre-heated in an oven to a temperature of about 70.degree. C. and
then dipped in a pre-prepared coagulant composition at a
temperature of about 55.degree. C. for a period of time and then
removed therefrom. Next, the coagulant-coated former is placed in a
drying oven at 70.degree. C. for a time sufficient to dry the
coagulant, typically about 5 minutes.
[0047] The coagulant-coated former is removed from the oven and
dipped into the compounded polyisoprene latex at ambient
temperature, or a temperature ranging from about 20.degree. C. to
about 25.degree. C. The coated former is removed and placed in oven
at a temperature of about 70.degree. C. for about 1 minute. The
glove and former are removed from oven and placed into water
leaching tank having a temperature of about 65.degree. C. for about
5 minutes. The glove and former are removed from the leaching tank
and placed dried at about 70.degree. C. for a period sufficient to
dry the glove, typically about 5 minutes. This is the end of the
first curing stage.
[0048] At the second curing stage, the glove and former are placed
in an oven heated to a temperature of about 120.degree. C. for
about 20 minutes. The glove and former are removed and cooled to
ambient temperature. Finally, the glove is stripped from the
former.
[0049] The gloves can be further treated in accordance with the
particular needs, such as using lubrication, coating, halogenation,
and sterilization techniques, all of which are conventional. Other
conventional steps can be incorporated into the general process as
well.
[0050] When prepared in accordance with the invention, elastomeric
articles such as gloves exhibit the following physical properties:
tensile strength of greater than about 3000 psi, elongation of
greater than about 750% at break, and a tensile modulus of less
than about 300 psi at 300% elongation as measured in accordance
with ASTM D412.
[0051] Other elastomeric polyisoprene articles can be prepared
using processes similar to those described herein, in combination
with conventional equipment and techniques readily available in the
art. For example, an elastomeric article in the form of condom can
be prepared using a condom former.
[0052] The following example further illustrates the advantages of
the invention and should not be construed as limiting the invention
to the embodiments depicted therein.
EXAMPLES
Example 1
Preparation of a Polyisoprene Glove
[0053] Polyisoprene latex (Kraton.TM. IR PR401 lot #000313 having
TSC 64.40% obtained from Shell International Corporation, Houston,
Tex.) was diluted with water. Sodium caseinate (obtained from
Technical Industries, Inc., Peacedale, R.I.) was then added to the
mixture and stirred at ambient temperature. While under continuous
stirring, zinc oxide and sulfur dispersions were added to the
mixture. Accelerator compounds ZDEC (from Akron Dispersions, Akron
Ohio), ZMBT, and DPG (from Akron Dispersions, Akron, Ohio) were
formulated into dispersions and then added. Wingstay.TM. L was
added and the mixture was stirred for approximately 15 minutes. The
composition was diluted to about 37.0% solids with water. The pH
was adjusted using ammonium hydroxide to pH 10.7. The composition
was maintained at a temperature of 25.degree. C. and stored under
continuous agitation for 24 hours at a temperature of less than
25.degree. C.
[0054] Accordingly, the following is a summary of the formulation
ingredients and their respective amounts. All percentages are
percentages by weight unless otherwise noted.
1 Latex Formulation: Ingredient Parts (phr) dry weight Polyisoprene
100.00 ZDEC 0.50 ZMBT 0.50 DPG 1.00 Sodium caseinate 0.75 ZnO 0.50
Sulfur 1.25 Wingstay .TM. L 2.00
[0055] A glove former was preheated to 100.degree. C. in an oven,
removed and dipped into a coagulant composed of soft water 80.65%,
calcium nitrate 13.65%, calcium carbonate 5.46%, wetting agent
(Surfonyl.TM. TG 0.2%), cellulose (Cellosize.TM. QP 52000) 0.04%)
at a temperature of 56.degree. C. for a period of 30 seconds and
removed. The coagulant-coated former was cooled to a temperature of
about 58.degree. C. and was placed in a drying oven at a
temperature of 100.degree. C. for a period of time sufficient to
dry the coagulant.
[0056] The coagulant-coated former was removed from the oven and
dipped into the compounded polyisoprene latex composition of
Formula 1 at a temperature of 25.degree. C. for a period of 0.8
minutes. The coated former was removed and placed into a pre-heated
oven at a temperature of 130.degree. C. for a period of 0.8
minutes.
[0057] The coated former was then removed from the oven and placed
into water leaching tank at a temperature of 50.degree. C. for a
period of 5.0 minutes. The former was removed from the leaching
tank and placed into an oven at a temperature of 70.degree. C. for
30 seconds.
[0058] The former was removed from the oven and dipped into a
silicone tank at a temperature of 40.degree. C. for 30 seconds. The
former was removed from the silicon tank and while still on the
former, the glove was beaded at the cuff using a beader roller.
[0059] The former were then placed into a second stage cure oven
and moved therethrough at zone temperatures ranging from
110.degree. C. to 135.degree. C. for a total time period lasting
for a period of 9.5 minutes. After exiting the curing oven, the
glove was subjected to a post-cure leaching. At this step, the
glove on the former was rinsed with water at a temperature of
70.degree. C. water for a period of about 1 minute.
[0060] The glove was placed in a slurry tank at a temperature of
55.degree. C. for 30 seconds. The slurry composition contained
85.2% water, 14.33% starch, 0.4% cellulose (Cellosize.TM. QP
52000), 0.4% sodium hypochlorite, 0.01% surfactant (Darvan.TM.),
and 0.02% Casastab.TM. T. The formers were then placed into a
post-slurry oven to dry the glove thereby producing the final
glove. The glove covered former was cooled and the glove was
stripped therefrom.
[0061] The physical properties of the glove produced by the above
process were evaluated. Samples were obtained from the gloves
exhibited average tensile strength values of 3810 psi, tensile
modulus value of 171 psi at 300% elongation, and 1125% elongation
at break as measured using ASTM D142.
Example 2
Comparative Data using Different Accelerator Formulations and
Process Conditions
[0062] Differing compounded polyisoprene latex compositions and
varying process parameters were used to prepare samples, the
physical properties of which were then tested and evaluated.
Compounded latex containing various accelerator compounds and phr
(parts per hundred) ratios were prepared in accordance with a
process similar to that of Example 1 Process for Preparation of
Polyisoprene Latex Composition", and pre-cured and stored at the
corresponding temperatures and conditions described or listed in
Table 1 below.
[0063] Test samples were prepared from compounded latex
formulations at various intervals over a total latex storage period
of eight (8) days. Each of samples 1 and 3 through 16 were then
prepared by heating plates to a temperature of about 70.degree. C.
for a period of about 5 minutes, and subsequently dipping the
plates in coagulant (35% calcium nitrate, 7% calcium carbonate,
0.03% Surfonyl# TG) at a temperature of about 55.degree. C. for a
period of about 10 seconds. The coagulant coated plates were then
dried at 70.degree. C. for a period of about 5 minutes. The coated
plates were then dipped into the compounded polyisoprene
compositions, which were stored and dipped at the corresponding
temperature shown in Table 1. The plates were leached with water at
a temperature of about 65.degree. C. for a period of about 3
minutes, and subsequently dried at a temperature of about
70.degree. C. for a period of about 5 minutes. The plates were then
cured at a temperature of 120.degree. C. for a period of about 20
minutes. The samples were then stripped from the plates.
[0064] Samples 2a and 2b were prepared using slightly different
process parameters and were obtained from articles prepared using
manufacturing-scale parameters and equipment. For each of samples
2a and 2b, a mold (glove former) was heated to a temperature of
about 55.degree. C. and dipped in coagulant (same coagulant as
above) at a temperature of about 55.degree. C. The
coagulant-covered mold was then dried in an oven at a temperature
of about 70.degree. C. for a period of about 3 minutes. The dried
coagulant-coated mold was removed from the oven and dipped into the
compounded latex composition for a period of about 12 seconds
dwelling time, removed for a period of about 6 seconds unsubmerged,
and then redipped for a further 8 seconds. The latex-coated mold
was leached at temperature of about 50.degree. C. for a period of
about 5 minutes, and subsequently cured at a temperature of about
135.degree. C. for a period of about 15 minutes.
[0065] The following Table I is a summary of the process parameters
and compounded latex formulations prepared:
2TABLE 1 Accelerator and Stabilizer Formulations and Process
Conditions Accelerator Composition (ZDEC/ ZMBT/DPG Stablizer Sample
No. Pbr ratio) (type/phr) Storage/Dipping Sample 1 1.0/1.0/0.50 Na
Caseinate/0.75 ambient/ambient Sample 2a 0.50/1.0/1.0 Na
Caseinate/0.75 20-25.degree. C./ambient Sample 2b 0.50/0.50/1.0 Na
Caseinate/0.75 20-25.degree. C./ambient Sample 3 1.0/1.0/0.50 Na
Caseinate/0.75 16-18.degree. C./ambient Sample 4* 1.9/0/0.50 Na
Caseinate/0.75 ambient/ambient Sample 5 0/2.1/0.50 Na
Caseinate/0.75 ambient/ambient Sample 6 1.0/1.0/0 Na Caseinate/0.75
ambient/ambient Sample 7 1.9/0/0 Na Caseinate/0.75 ambient/ambient
Sample 8 1.0/0.50/0.25 Na Caseinate/0.75 ambient/ambient Sample 9
1.0/1.0/0.50 DS10/0.75 ambient/ambient Sample 10 1.0/1.0/0.50
ES/0.3 ambient/ambient Sample 11 1.0/1.0/0.50 Tween .RTM. 80/0.75
ambient/ambient Sample 12** 1.0/1.0/0.50 Na Caseinate/0.75
ambient/ambient Sample 13*** 1.0/1.0/0.50 Na Caseinate/0.75
ambient/ambient Sample 14**** 1.0/1.0/0.50 Na Caseinate/0.75
ambient/ambient Sample 15 1.0/1.0/0.50 Na Caseinate/0.75
16-18.degree. C./ambient Sample 16 1.0/1.0/0.50 Na Caseinate/0.75
16-18.degree. C./ambient *Sample 4 compounded latex exhibited about
4% coagulation indicating significant precipitation of solids out
of the formulation. **The precure temperature for Sample 12 was
ambient temperature (20.degree. C.). ***The precure time for Sample
13 was a period of about 2.5 hours (150 minutes). ****The precure
time for Sample 14 was a period of about 1 hour (60 minutes).
[0066] DS10 refers to Rhodacal.RTM. DS-10 which comprises sodium
dodecylbenzene (branched) available from Rhone-Poulenc, Inc.,
Dayton, N.J. ES refers to Rhodapex ES which comprises sodium lauryl
(3) sulfate available from Rhone-Poulenc, Inc., Dayton, N.J.
Tween.RTM. 80 comprises polysorbate 80 and polyoxyethylene (20)
sorbitan monooleate available from ICI Americas, Inc. (Wilmington,
Del.). Unless indicated otherwise, "ambient" temperature was
measured as approximately 20.degree. C. Precure temperature and
time for each of Samples 1 through 11 was a temperature of
30.degree. C. for a period of approximately 2 hours (120
minutes).
[0067] Each of the samples was then evaluated for tensile strength
in accordance with ASTM D 412-98a "Standard Test Methods for
Vulcanized Rubber and Thermoplastic Elastomers--Tension" (1998)
with no exceptions using an Instron.RTM. testing apparatus. The
average tensile strength values for each sample were calculated
from averaging five individual samples per day storage value. The
average tensile strength values for each of the samples tested are
summarized in the following Table 2:
3TABLE 2 Tensile Strength Corresponding to Differing Latex Storage
Periods Tensile Strength (psi) @ Compounded Latex Storage Time
Sample # Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 1
2698 3648 3398 3080 -- 2651 2548 -- 2410 2a -- 3768 3640 3839 -- --
3441 3541 -- 2b -- 3498 3782 3882 -- -- 3939 3043 -- 3 2201 2413
3192 3158 3288 3154 3008 3000 2909 4 3242 3609 -- 3515 3244 3096
2498 -- 2464 5 1483 1733 -- 2149 1590 1534 1478 -- 1358 6 No
tensile measured/sample did not break 7 No tensile measured/sample
did not break 8 1018 1063 3051 -- 2177 -- -- 1802 -- 9 -- 2566 914
2843 -- -- -- -- -- 10 -- 1278 2520 839 -- -- -- -- -- 11 -- 2407
2901 3042 2834 -- -- -- -- 12 -- 2450 -- -- -- 2374 -- 2212 -- 13
2544 3213 3181 2974 2770 -- 2393 -- -- 14 1595 2221 2838 -- 2383 --
-- 1805 -- 15 2084 2974 2452 3497 3312 3075 3056 2979 2968 16 2194
2904 3064 3110 3170 3002 2885 2902 2746
[0068] As can be seen from the above data, synthetic elastomeric
polyisoprene samples prepared in accordance with the invention can
exhibit significantly elevated tensile strengths of about 3000 psi,
even after using compounded latex which has been stored for periods
of at least 5 days and lasting up to about seven (7) days. In
general, the best tensile strength values per day latex storage
were obtained using the combination of the three preferred
accelerator compounds (ZDEC/ZMBT/DPG) and preferred phr ratios
(0.50 to 1.00/0.50 to 1.00/0.50 to 1.00 phr), as well as the
preferred stabilizer, sodium caseinate. Samples prepared without
one of the three preferred accelerator compounds exhibited
significantly lower tensile strength values, as can be seen from
Samples 4, 5, 6 and 7. Based on the results of testing of samples 6
and 7, the tensile strength values for these samples failed to meet
minimum FDA regulatory standards required for elastomeric materials
to be used for surgeon's gloves, which is set at about 2479
psi.
[0069] Samples 3, 15 and 16 were prepared from compounded latex
comprising the preferred accelerator composition ZDEC/ZMBT/DPG in a
1.0/1.0/0.50 phr ratio, with sodium case mate as the stabilizer,
and stored at temperatures ranging from about 16.degree. C. to
about 18.degree. C. as seen in Table 1. As can be seen from Table
2, these samples exhibited the highest combination of storage
longevity in relation to high tensile strength values.
[0070] Sample 4, which was prepared from an accelerator composition
without the thiazole compound, demonstrated high tensile strength
values. This compounded latex, however, exhibited an undesirable
amount of precipitation of solids out of the composition.
[0071] Based on the tensile data that was compiled for samples 9,
10 and 11, the use of stabilizers in the compounded latex other
than preferred stabilizer sodium case mate resulted in samples with
significantly reduced tensile strength per given storage period
when compared to samples 1 through 3 and 15 and 16, for
example.
[0072] Samples 12, 13 and 14 were prepared from latex compositions
under varying pre-cure time and temperature parameters. As can be
seen from Table 2, deviations in pre-cure temperature and time
conditions can also significantly effect the physical properties of
the resulting material as well.
Industrial Applicability
[0073] The invention is useful in manufacturing process for
elastomeric articles composed of polyisoprene. The invention
affords the ability to produce synthetic polyisoprene articles
which closely mimic the physical properties of elastomeric articles
made from natural rubber latex. The invention can be advantageously
incorporated into the manufacturing of surgical gloves, condoms,
probe covers, dental dams, finger cots, catheters, and the
like.
[0074] The invention has been described with reference to various
specific and preferred embodiments and techniques. However, it
should be understood that many variations and modifications can be
made while remaining within the spirit or scope of the invention as
defined by the claims set forth below.
* * * * *